הזדמנות עסקית | סין | 96379 | ייבוא מישראל | כימיה, רפואה ופרמצבטיקה | 11/02/2019

Ophthalmic medical devices, drugs in field of ophthalmology/CNS/Oncology

Our company has a working capital of over 5.2 Billion USD and we invest over 12.5% of the annual revenue in novel projects. In the past three years, we acquired an Israeli company (iOptima) to bring in a medical device for the ophthalmology market in which we are particularly strong. We think that other technological developments coming from Israel are good opportunities to pursue. 

We are specifically looking for new ophthalmic medical devices, drugs in field of ophthalmology/CNS/Oncology with US FDA ANDA or EU MA (for distribution or tech transfer), or joint development with novel formulation platforms. We can discuss several business models. 

The purpose of this email is to connect with the right person to guide us on what would be the best way to start screening companies that are open to cooperating with Chinese partners.

We have over 22 years of experience, leading some Specialized Drugs Market.  With over 4,000 employees, the company engages in the R&D, Manufacture, Sales and Marketing processes related to Biological, Chemical and Traditional Chinese Medicine (TCM) Drugs.

 

פרטים על ההזדמנות

סין
  • Country:
    China
  • Number:
    96379
  • Activity:
    Import From Israel
  • Branch:
    Chemistry, Medicine, Pharmaceuticals and Cosmetics
  • Published:
    11/02/2019
Member of trade organization, association or chamber of commerce :
Change the CAPTCHA code

חדשות חמות